<DOC>
	<DOCNO>NCT01289457</DOCNO>
	<brief_summary>The goal clinical research study learn combination clofarabine , idarubicin , cytarabine , combination fludarabine , idarubicin , cytarabine help control AML MDS . The safety study drug combination also study .</brief_summary>
	<brief_title>Clofarabine , Idarubicin , Cytarabine ( CIA ) Versus Fludarabine , Idarubicin , Cytarabine ( FLAI ) Acute Myelogenous Leukemia ( AML ) High-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>The Study Drugs : Clofarabine design interfere growth development cancer cell . Idarubicin design cause break strand DNA ( genetic material cell ) . This may cause cancer cell die . Cytarabine Fludarabine design insert DNA cancer cell stop DNA repairing . Study Groups : If find eligible take part study , assign study group base join study . Up 4 group 6 participant enrol Phase I portion study . Up 280 participant enrol Phase II . Phase I : If enrol Phase I portion , dose clofarabine receive depend join study . The first group participant receive low dose level clofarabine . Each new group receive high dose clofarabine group , intolerable side effect see . This continue high tolerable dose clofarabine find . All participant receive dose level idarubicin cytarabine . Phase II : If enrol Phase II portion , randomly assign ( flip coin ) 1 2 group : - If Group 1 , receive clofarabine , idarubicin , cytarabine . You receive clofarabine high dose tolerate Phase I portion . - If Group 2 , receive fludarabine , idarubicin , cytarabine . Study Drug Administration : Study drug ( ) give call `` cycle . '' Each cycle 28 day . Phase I : On Days 1-5 : - You receive clofarabine vein 1 hour . - You receive cytarabine vein 2 hour . - On Days 1-3 , receive idarubicin vein 30 minute . Phase II ( Induction ) : The first cycle study drug call Induction . If doctor think need , 2 Induction cycle . If Group 1 : On Days 1-5 cycle : - You receive clofarabine vein 1 hour . - You receive cytarabine vein 2 hour . - On Days 1-3 , receive idarubicin vein 30 minute . If Group 2 : On Days 1-5 cycle : - You receive fludarabine vein 30 minute . - You receive cytarabine vein 2 hour . - On Days 1-3 , receive idarubicin vein 30 minute . If doctor think need , may receive less 5 day treatment induction cycle . If doctor think need , dose level reduce Induction . Phase II ( Consolidation ) : If disease respond study drug , may receive 6 cycle study drug . This call Consolidation . If Group 1 : On Days 1-3 cycle : - You receive clofarabine vein 1 hour . - You receive cytarabine vein 2 hour . - After 1 2 hour receive cytarabine Days 1-2 , receive idarubicin vein 30 minute . If Group 2 : On Days 1-3 cycle : - You receive fludarabine vein 30 minute - You receive cytarabine vein 2 hour . - After 1 2 hour receive cytarabine Days 1-2 , receive idarubicin vein 30 minute If cancer completely respond Cycle 1 , may repeat induction ( Cycle 1 ) . If cancer completely respond , begin consolidation cycle . If doctor think need , may receive less 3 day treatment consolidation cycle . Study Visits : You physical exam , include measurement vital sign start cycle . Blood ( 2 teaspoon ) draw routine test every 3-7 day . On Day 28 every 2-3 cycle ( +/- 7 day ) , doctor think need , bone marrow aspirate check status disease . To collect bone marrow aspirate , area hip numb anesthetic , small amount bone marrow withdrawn large needle . Length Study : You may continue take study drug long doctor think best interest 8 total cycle . You longer able take study drug disease get bad intolerable side effect occur . Your participation study complete long-term follow-up . Long-Term Follow-up : Every 3 month 1 year study , call ask feeling , side effect may , drug may take . These call last 5 minute . This investigational study . Cytarabine Idarubicin FDA approve commercially available treatment AML . Fludarabine FDA approve commercially available treatment chronic lymphocytic leukemia ( CLL ) . Clofarabine FDA approve commercially available treatment acute lymphoblastic leukemia ( ALL ) . The combination study drug investigational . Up 292 patient take part Phase I Phase II study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Sign IRBapproved inform consent document . 2 . Age 18 60 . Patients age 60 principal investigator ( PI ) approval 3 . Diagnosis newly diagnose AML [ acute promyelocytic leukemia ( APL ) ] highrisk ( intermediate2 high IPSS &gt; 10 % blast , include CMML ) MDS . Prior therapy hydrea use single two day dose cytarabine ( 3 g/m2 ) emergency use 24 hour prior start study therapy allow . Prior therapy MDS AHD allow . 4 . ECOG performance status &lt; /= 3 study entry . 5 . Organ function define ( unless due leukemia ) : Serum creatinine &lt; /= 3 mg/dL Total bilirubin &lt; /= 2.5 mg/dL , ALT ( SGPT ) &lt; /= 3 * ULN &lt; /= 5 * ULN related disease . 6 . Women childbearing potential must negative serum urine pregnancy test within 7 day must agree practice acceptable contraceptive method . Men must agree father child agree use condom partner child bear potential . 7 . Cardiac ejection fraction &gt; /= 40 % ( either cardiac echo MUGA scan ) . Documentation recent ( &lt; /= 6 month screen ) outside report acceptable . 1 . Breast feeding female 2 . Patients uncontrolled active infection ( viral , bacterial , fungal eligible ) . 3 . Patients active secondary malignancy eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>High-Risk Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Idamycin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
</DOC>